Urinary fatty acid binding protein 2 as a biomarker of intestinal injury in pediatric celiac disease
Frontiers in Pediatrics · 10.06.2026 · 14
DOI: 10.3389/fped.2026.1838294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pediatrics, online erschienen am 10.06.2026. Verfasst von Vijay Mehta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Gastroenterology, Orlando Health Arnold Palmer Hospital for Children, Orlando, FL, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Celiac disease (CeD) is an autoimmune enteropathy triggered by gluten in genetically predisposed individuals, causing intestinal damage and impaired gut barrier integrity. Current diagnostic methods, such as serology and intestinal biopsy, are costly and invasive. Intestinal fatty acid binding protein (FABP2), exclusively expressed in the cytosol of mature enterocytes and released during injury, offers a potential non-invasive alternative biomarker. This study aimed to evaluate urinary FABP2 levels in pediatric patients undergoing gastrointestinal assessment or CeD follow-up to determine its potential as a non-invasive biomarker of intestinal integrity.
Methods
In this retrospective cross-sectional study, urinary FABP2 was measured in 103 pediatric patients evaluated for intestinal permeability using the lactulose/mannitol test. Based on serology and symptomatology, patients were categorized as controls ( n = 65), CeD on gluten-free diet (GFD) > 6 months ( n = 26), or active CeD ( n = 12). Associations between FABP2 levels, serology, symptoms, and diagnosis were analyzed.
Results
FABP2 levels were significantly elevated in active CeD patients (47.7 pg/mL) compared with controls (9.65 pg/mL) ( p < 0.05), but not in CeD patients on GFD (15.0 pg/mL). A receiver operating characteristic curve analysis confirmed the diagnostic potential of FABP2 as a biomarker for celiac disease (area under the curve = 0.7269; cutoff = 23.7 pg/mL; sensitivity = 66.7%, specificity = 76.9%).
Conclusion
Our findings indicate that urinary FABP2 reflects intestinal epithelial injury and may serve as a non-invasive biomarker for assessing gut integrity and disease activity in CeD. However, larger prospective studies with histological correlation are needed to validate its diagnostic utility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Gastroenterology, Orlando Health Arnold Palmer Hospital for Children, Orlando, FL, United States.
- Specialty Diagnostic Clinical and Translational Research Lab, Orlando Health Arnold Palmer Hospital for Children, Orlando, FL, United States.
- University of Central Florida, Orlando, FL, United States.
- Orlando Health Medical Group Pediatric Specialty Practice Resources, Orlando, FL, United States.
Zitieren
APA
Mehta, V., Kapoor, N., Milliron, C., Stoeckel, N., Ballelos, E., Tiqui, K., Deb, C., Abomoelak, B., Schreck, M., & Mehta, D. (2026). Urinary fatty acid binding protein 2 as a biomarker of intestinal injury in pediatric celiac disease. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1838294
Vancouver
Mehta V, Kapoor N, Milliron C, Stoeckel N, Ballelos E, Tiqui K, et al. Urinary fatty acid binding protein 2 as a biomarker of intestinal injury in pediatric celiac disease. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1838294
BibTeX
@article{Mehta2026,
author = {Mehta, Vijay and Kapoor, Nidhi and Milliron, Chloe and Stoeckel, Noah and Ballelos, Edwin and Tiqui, Katrina and Deb, Chirajyoti and Abomoelak, Bassam and Schreck, Mary and Mehta, Devendra},
title = {Urinary fatty acid binding protein 2 as a biomarker of intestinal injury in pediatric celiac disease},
journal = {Frontiers in Pediatrics},
year = {2026},
volume = {14},
doi = {10.3389/fped.2026.1838294}
}
EUVIMED